Invitae's Q3 Revenues Jump on Increased Test Volume | GenomeWeb

NEW YORK (GenomeWeb) – Invitae reported Thursday after the close of the market that its sales increased seven-fold year over year for the third quarter.

For the three months ended Sept. 30, the firm reported revenues of $2.2 million, up from $310,000 for Q3 2014 but short of the consensus Wall Street estimate of $2.6 million.

The company billed more than 5,100 reports during the third quarter, a 360 percent increase compared to the year ago period, and accessioned more than 5,400 samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.